Staying updated on the Johnson & Johnson stock performance is crucial for investors. As of today, the company’s stock is trading at $152.94, marking a 0.22% increase over the past 24 hours.
Johnson & Johnson, a leading healthcare company, operates through three main segments: Consumer Health, Pharmaceutical, and Medical Devices. Understanding the dynamics of its stock price in the current market is essential for both current shareholders and potential investors.
Our analysis will delve into the latest trading data and key factors influencing Johnson & Johnson‘s market position, providing a comprehensive overview for those interested in the healthcare sector.
Current JNJ Stock Price and Market Position
Understanding Johnson & Johnson’s current stock price and market position is crucial for investors looking to make informed decisions. The company’s stock is considered a blue-chip investment, and its current price is an important metric for market analysis.
Today’s Price Movement and Trading Volume
As of today, JNJ’s stock price is $152.94 USD, with a day range of $152.21 – $153.48. The previous close was $152.61, indicating a slight increase in the stock’s value. The trading volume today is a key indicator of the stock’s liquidity and market interest. With a day change of $0.33, JNJ stock has risen by 2.18% compared to the previous week.
Market Capitalization and Comparative Position
Johnson & Johnson’s market capitalization stands at $367.98 billion, positioning it as a leading player in the healthcare sector and within the S&P 500. The company’s market value reflects its stability and influence in the pharmaceutical industry. Over the last year, Johnson & Johnson has shown a 2.28% increase in its stock price, despite a -2.27% fall over the month, demonstrating its resilience in varying market conditions.
Johnson & Johnson Company Overview
Johnson & Johnson’s journey began in 1886, and since then, it has grown into one of the world’s largest healthcare companies. The company has a rich history of innovation and a diverse portfolio that includes medical devices, pharmaceuticals, and consumer packaged goods.
Company History and Core Business Segments
Johnson & Johnson operates through two main segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on the development and sale of pharmaceutical products for various therapeutic areas, including immunology, infectious diseases, and oncology. The MedTech segment is involved in the manufacture and sale of medical devices.
Global Presence and Market Leadership
With operations in more than 60 countries and products sold in virtually every country worldwide, Johnson & Johnson has a significant global presence. The company is a leader in several key therapeutic fields, including cardiovascular and metabolism, and pulmonary hypertension. This market leadership contributes to the company’s strong financial performance and influences its stock price positively.
Johnson & Johnson’s diverse portfolio and global reach position it as a major player in the healthcare field, driving innovation and delivering value to patients and investors alike.
JNJ Stock Price Historical Performance
Understanding the historical performance of JNJ stock is essential for investors looking to make informed decisions. Johnson & Johnson’s stock price has been influenced by various market and economic factors over the years.
52-Week Price Range Analysis
Over the past 52 weeks, JNJ’s stock price has ranged from $140.68 to $169.99. This range indicates the stock’s volatility and helps investors identify key support and resistance levels. The current price movement within this range suggests that the stock is experiencing a normal fluctuation.
5-Year Performance Trends
Analyzing JNJ’s 5-year performance reveals a 3.91% change in stock value. This moderate growth indicates Johnson & Johnson’s stability in the market. The 3-year change, however, shows a -15.54% decline, highlighting the impact of different market cycles on the stock’s performance.
Dividend History and Yield Analysis
Johnson & Johnson has a history of paying consistent dividends, with a current dividend yield of 3.4% and a payout ratio of 55%. This indicates that the company is committed to returning value to its shareholders. The relatively stable dividend yield makes JNJ an attractive option for income-focused investors.
JNJ’s beta of 0.41 signifies that the stock is less volatile than the broader market, making it a defensive stock that can provide stability in uncertain economic conditions.
Financial Health Indicators
Johnson & Johnson’s financial health is a critical aspect of its stock performance, with several key indicators providing insight into the company’s overall stability. The company’s financial indicators are a testament to its strong market position and operational efficiency.
Revenue and Earnings Growth
Johnson & Johnson has demonstrated significant revenue and earnings growth, with a trailing twelve months (TTM) revenue of $89.33 billion and earnings of $21.81 billion. The company’s earnings grew by 28.1% over the past year, indicating a strong upward trend. As noted by a financial analyst, “Johnson & Johnson’s revenue growth is a result of its diversified business segments and strategic investments in research and development.”
“The company’s ability to consistently deliver strong revenue and earnings growth is a testament to its robust business model.”
Profit Margins and Operating Efficiency
The company’s gross margin stands at 68.90%, with a net profit margin of 24.41%, highlighting its operational efficiency. Johnson & Johnson’s revenue per employee is $643,150, further emphasizing its productivity.
As stated by a company representative, “Our focus on operational efficiency has enabled us to maintain a competitive edge in the market.”
Debt Levels and Cash Position
Johnson & Johnson’s debt/equity ratio is 66.9%, indicating a moderate level of indebtedness. The company’s net income (FY) is $14.07 billion, demonstrating its ability to generate significant earnings. The company’s financial flexibility is crucial in navigating economic downturns and investing in growth opportunities. With a strong cash position, Johnson & Johnson is well-equipped to continue its growth trajectory.
Recent Quarterly Performance
The latest quarterly earnings report from Johnson & Johnson has exceeded expectations, showcasing the company’s strong performance. With earnings per share (EPS) of $2.77, the company beat analyst estimates of $2.58 by 7.33%. This positive earnings surprise was driven by robust revenue growth, with the company reporting $21.89 billion in revenue against the estimated $21.56 billion.
Latest Earnings Results vs. Estimates
Johnson & Johnson’s latest report highlighted a significant beat in earnings per share. The 7.33% surprise was a result of better-than-expected performance across various segments. The company’s revenue growth was driven by strong sales in its key business divisions. This positive data indicates a healthy operational performance.
- Earnings per share: $2.77 (vs. estimated $2.58)
- Revenue: $21.89 billion (vs. estimated $21.56 billion)
- Earnings surprise: 7.33%
Segment Performance Breakdown
The segment performance breakdown reveals that Johnson & Johnson’s business divisions are performing well. The company’s diverse portfolio, including pharmaceuticals, medical devices, and consumer health products, contributed to the overall growth. The trailing twelve months (TTM) data also supports the positive trend, indicating sustained performance over time.
- Pharmaceuticals segment showed significant growth.
- Medical devices segment performed steadily.
- Consumer health products segment contributed positively.
Looking ahead, the next earnings report is scheduled for July 16, 2025. Investors will be watching key metrics and analyst estimates closely to gauge the company’s continued performance.
Analyst Ratings and Price Targets
The current analyst consensus for Johnson & Johnson stock offers valuable insights for investors looking to make informed decisions. With 60 analysts covering the stock, the consensus rating provides a detailed perspective on its potential.
Current Analyst Consensus
The analyst community has provided a range of ratings for Johnson & Johnson, reflecting varying opinions on its market performance. According to recent research, 22 analysts have submitted estimates of revenue or earnings, contributing to the overall consensus. The rating breakdown indicates a generally positive outlook, although individual opinions vary.
- Strong valuation metrics contribute to a positive outlook.
- Past performance is a key factor in the current consensus.
Price Target Range and Projections
Analysts have set a price target range for Johnson & Johnson between $153.00 and $185.00, reflecting their research and analysis. This range indicates the potential value of the stock based on various factors, including the company’s financial health and dividend yield. When considering Johnson & Johnson for your portfolio, it’s essential to look beyond consensus ratings and understand the factors influencing these projections.
Conclusion: JNJ Stock Outlook and Investment Considerations
Johnson & Johnson’s stock presents a compelling opportunity for investors seeking value and dividend income. Currently trading at 52.7% below its estimated fair value, JNJ stock is an attractive option for value investors. The company’s reliable 3.4% dividend yield and long history of dividend increases make it a staple for income-focused investors.
JNJ’s stock has outperformed the US Pharmaceuticals industry over the past year, despite underperforming the broader US market. This resilience makes it a viable candidate for various investment portfolios, from conservative income strategies to balanced growth and income approaches.
Investors should monitor upcoming product approvals, litigation risks, and broader economic factors that could impact JNJ’s performance and growth. With its strong fundamentals and attractive dividend, Johnson & Johnson stock is well-positioned to continue delivering value to its investors.